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Parents/guardians completed the Weiss Functional Impair-
ment Rating Scale-Parent Report (WFIRS-P) at baseline 
and at week 9 or early termination. p values were nominal 
and not corrected for multiple comparisons. Of 267 rand-
omized patients, 200 completed the study (LDX 99, ATX 
101). At baseline, mean WFIRS-P total score in the LDX 
group was 0.95 [standard deviation (SD) 0.474; 95 % con-
fidence interval (CI) 0.87, 1.03] and in the ATX group was 
0.91 (0.513; 0.82, 1.00). Scores in all WFIRS-P domains 
improved from baseline to endpoint in both groups, with 
least-squares mean changes in total score of −0.35 (95 % 
CI −0.42, −0.29) for LDX and −0.27 (−0.33, −0.20) for 
ATX. The difference between LDX and ATX was statisti-
cally significant (p < 0.05) for the Learning and School 
(effect size of LDX vs ATX, 0.43) and Social Activities 
(0.34) domains and for total score (0.27). Both treatments 
reduced functional impairment in children and adolescents 
with ADHD; LDX was statistically significantly more effec-
tive than ATX in two of six domains and in total score.
Keywords Atomoxetine · Attention-deficit/hyperactivity 
disorder · Functional impairment · Lisdexamfetamine 
dimesylate · Weiss Functional Impairment Rating  
Scale-Parent Report
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is charac-
terized by the core symptoms of inattention, hyperactivity, 
and impulsivity. ADHD is also associated with substantial 
functional impairments that can affect social, academic, 
and occupational activities throughout life [6]. Indeed, the 
Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition, Text Revision (DSM-IV-TR) [3], the recent 
Abstract Attention-deficit/hyperactivity disorder (ADHD) 
is associated with functional impairments in multiple 
domains of patients’ lives. A secondary objective of this 
randomized, active-controlled, head-to-head, double-blind, 
dose-optimized clinical trial was to compare the effects 
of lisdexamfetamine dimesylate (LDX) and atomoxetine 
(ATX) on functional impairment in children and adolescents 
with ADHD. Patients aged 6–17 years with an ADHD Rat-
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5th edition of the DSM (DSM-5) [2], and the International 
Classification of Diseases, 10th revision [43] all specify 
evidence of functional impairment as a diagnostic criterion 
for ADHD. The impact of such impairment on a patient’s 
daily life commonly provides the motivation to seek medi-
cal treatment [37]. ADHD treatment should, therefore, aim 
not only to improve symptoms but also to reduce functional 
impairment. This is reflected in European regulatory guid-
ance for clinical trials of ADHD medications, which state 
that such trials should include a functional outcome meas-
ure [30].
Lisdexamfetamine dimesylate (LDX) is a long-acting 
prodrug psychostimulant. Clinical trials in children, ado-
lescents, and adults have shown LDX to be effective in 
the treatment of ADHD and to have a tolerability profile 
consistent with that of psychostimulant therapy [7, 8, 22, 
31]. LDX is approved as a first-line treatment for ADHD 
in the USA, Canada, Brazil, and Australia and is the first 
long-acting amfetamine-based medication to be approved 
in Europe, where it is licensed in select countries for the 
treatment of children and adolescents with ADHD when 
response to previous methylphenidate (MPH) treatment 
is considered clinically inadequate by the supervising 
specialist.
Study SPD489-317 (ClinicalTrials.gov NCT01106430) 
was a 9-week, head-to-head, randomized, double-blind trial 
comparing LDX with atomoxetine (ATX), a non-stimulant 
noradrenaline reuptake inhibitor [27]. The study was con-
ducted in a population of children and adolescents with 
ADHD in Europe and North America who were judged to 
have responded inadequately to MPH therapy (defined in 
‘Methods’). The primary efficacy outcome was the time to 
clinical response [defined as a Clinical Global Impressions-
Improvement (CGI-I) score of 1 (very much improved) 
or 2 (much improved)]. This was significantly shorter 
for patients receiving LDX than for those receiving ATX 
[12.0 days (95 % confidence interval (CI) 8.0, 16.0) vs 
21.0 days (15.0, 23.0); p = 0.001] [27].
Secondary efficacy outcomes revealed that significantly 
higher proportions of patients in the LDX group exhibited 
a clinical response (CGI-I score of 1 or 2) compared with 
those in the ATX group and that patients receiving LDX 
showed significantly greater improvements in ADHD symp-
toms (assessed using the ADHD Rating Scale IV [ADHD-
RS-IV]) than those receiving ATX, at every study visit in 
weeks 1–9 [27]. Assessment of these outcomes used the 
‘last observation carried forward’ approach to missing data. 
The safety and tolerability profiles of both treatments were 
consistent with findings from previous clinical trials [27].
Here, we report the effects of LDX and ATX treat-
ment on functioning in study SPD489-317, as measured 
using a disorder-specific instrument, the Weiss Functional 
Impairment Rating Scale-Parent Report (WFIRS-P) [29]. 
This was a pre-specified secondary objective of study 
SPD489-317.
Methods
This double-blind, randomized, active-controlled, parallel-
group clinical trial was conducted between June 2010 and 
July 2012 at 51 sites in Europe, the USA, and Canada. The 
protocol was approved by an institutional review board, 
an independent ethics committee, or a regulatory agency 
at each centre, and the study was conducted in accordance 
with the International Conference on Harmonisation of 
Good Clinical Practice guideline and with local ethical and 
legal requirements. Full details of the study design have 
been published previously [27].
Study population
Patients aged 6–17 years were eligible for enrolment if 
they met the DSM-IV-TR criteria for a primary diagno-
sis of ADHD, had a baseline ADHD-RS-IV total score of 
28 or higher (indicating at least moderately severe symp-
toms), and had previously experienced (or were experienc-
ing) an inadequate response to MPH treatment. ‘Inadequate 
response’ was judged by investigators and included, but 
was not limited to: variable or incomplete symptom con-
trol; inadequate duration of action; and the potential (in 
the investigator’s opinion) for the patient to benefit clini-
cally from an alternative to MPH treatment. Patients were 
excluded if they had been exposed to amfetamine or ATX 
previously, if they had experienced intolerable side effects 
with previous MPH treatment, or if their symptoms were 
well controlled with acceptable tolerability on their cur-
rent ADHD medication. Patients were also excluded if they 
had failed to respond to more than one previous course 
of MPH (defined as worsened, unchanged, or minimally 
improved symptoms) or if they had previously been treated 
with more than one formulation of MPH [except short-term 
(≤4 weeks) dose titration with immediate-release MPH, 
provided they experienced an adequate response]. Fur-
thermore, patients were excluded if they had a comorbid 
psychiatric diagnosis with significant symptoms or other 
symptomatic manifestations (e.g. agitated states, marked 
anxiety, or tension) that contraindicated treatment with 
LDX or ATX in the opinion of the investigator. Patients 
with a conduct disorder were also excluded, but opposi-
tional defiant disorder was not exclusionary.
Study design
After discontinuing any previous psychoactive medica-
tion for a 7-day washout period, patients were randomized 
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in a 1:1 ratio to receive once-daily treatment with LDX or 
ATX for 9 weeks. Doses of LDX and ATX were adjusted 
at weekly intervals over a 4-week period until an ‘accept-
able’ response was achieved; this was defined as a reduc-
tion of at least 30 % in ADHD-RS-IV total score from 
baseline and a CGI-I score of 1 or 2 (very much improved 
or much improved) with tolerable side effects [27, 28, 33]. 
Patients in the LDX group initially received 30 mg/day, 
and if required, the dose was titrated to 50 mg/day and then 
to 70 mg/day. Patients in the ATX group weighing 70 kg 
or more initially received 40 mg/day, and if required, the 
dose was titrated to 80 mg/day and then to 100 mg/day. 
Patients in the ATX group weighing less than 70 kg initially 
received approximately 0.5 mg/kg/day, and if required, the 
dose was titrated to a final target dose of 1.2 mg/kg/day, 
with a maximum permitted dose of 1.4 mg/kg/day.
Functional impairment assessments
Change in functional impairment, assessed using the 
WFIRS-P, was a secondary efficacy outcome of the study 
(the primary efficacy and safety outcomes have been pub-
lished previously [27]). The WFIRS-P was completed 
by each patient’s parents or legal guardians at baseline 
(week 0) and either at week 9 or at an early termination 
visit attended by patients who withdrew from the study.
The WFIRS-P was designed to provide a disorder-spe-
cific measure of functioning in children and adolescents 
with ADHD and has been shown to have good internal 
consistency and moderate convergent validity with other 
instruments [29]. The questionnaire comprises 50 items, 
grouped into six domains (Family, Learning and School, 
Life Skills, Child’s Self-Concept, Social Activities, and 
Risky Activities). Each item relates to the previous month 
and is scored on a four-point Likert scale (0 = never or not 
at all; 1 = sometimes or somewhat; 2 = often or much; 
3 = very often or very much) or recorded as not applica-
ble [29]. This study used an early version of the WFIRS-P 
[41]; the current version refers to the Learning and School 
domain as the School domain [40]. Higher WFIRS-P scores 
indicate more severe functional impairment.
Data have not yet been published on the minimum 
changes in WFIRS-P scores from baseline to endpoint 
within a treatment group that correspond to clinically rel-
evant improvements in functional impairment in patients 
with ADHD. One-half the standard deviation (SD) at 
baseline [34, 44] has been recommended as a value for 
the minimum clinically important difference in WFIRS-
P scores by the developers of the instrument and has 
been used in previous studies [32]. To our knowledge, 
no data exist on minimum clinically important differ-
ences between two active medications in improvements in 
WFIRS-P scores.
Statistical analysis
Sample size was calculated as previously described and 
was based on the primary efficacy outcome of time to clini-
cal response (and not on any secondary outcome) [27]. 
WFIRS-P data were analysed for the Full Analysis Set, 
which comprised all patients who were randomized and 
received at least one dose of study medication, and which 
was based on the intention-to-treat principle. Baseline and 
week 9 scores were the observed values; endpoint was 
defined as the last on-treatment, post-baseline visit with a 
valid WFIRS-P assessment (endpoint is therefore equiva-
lent to ‘last observation carried forward’ at week 9).
Changes in WFIRS-P total or domain scores from base-
line to week 9 and endpoint were analysed using an analy-
sis of covariance (ANCOVA) model with treatment group 
and country as fixed effects and baseline score as a covari-
ate. The model did not include interaction terms. A formal 
statistical comparison between LDX and ATX for the least-
squares (LS) mean change in WFIRS-P total and domain 
scores from baseline to endpoint was pre-specified in the 
study protocol. A formal statistical analysis of the change 
from baseline to week 9 or endpoint within each treatment 
group was not pre-specified, but was performed ad hoc, and 
was not therefore protected against type I error. No adjust-
ment of p values for multiple comparisons was pre-speci-
fied or performed for secondary efficacy variables; p values 
less than 0.05 should therefore be regarded as representing 
nominal statistical significance. Effect sizes were calcu-
lated as the difference in LS mean change in scores from 
baseline between the LDX and ATX groups divided by the 
root mean square error obtained from the ANCOVA model. 
Effect sizes of 0.2, 0.5, and 0.8 are considered to indicate 
small, medium, and large differences between treatment 
groups, respectively, and are more often used for compar-
isons of an active drug versus placebo than of one active 
drug versus another [25].
Results
Patient disposition and baseline characteristics
Patients (n = 267) were enrolled at 51 study sites in the 
USA (n = 138), Germany (n = 42), Canada (n = 35), 
Spain (n = 22) Hungary (n = 20), Sweden (n = 6), Bel-
gium (n = 2), Italy (n = 1), and Poland (n = 1). Of 267 
patients randomized (LDX, n = 133; ATX, n = 134), 262 
received at least one dose of study drug and were included 
in the Full Analysis Set (LDX, n = 127; ATX, n = 135). 
Of these, 200 (74.9 %) completed the study (LDX, n = 99; 
ATX, n = 101). Based on the intention-to-treat principle, 
one patient who was randomized to ATX but received LDX 
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in error was included in the ATX group in the Full Analysis 
Set. The most common reasons for discontinuation in the 
LDX group were adverse events (n = 8; 6.0 %) and with-
drawal by the patient (n = 8; 6.0 %); the most common 
reasons in the ATX group were lack of efficacy (n = 13; 
9.7 %) and adverse events (n = 10; 7.5 %).
Baseline demographic characteristics were similar 
in both treatment groups [27]. The mean age of patients 
at baseline was 10.6 years (SD 2.93); 74.0 % of patients 
were children (aged 6–12 years), and 75.2 % were male. 
In both treatment groups, the most frequently reported rea-
son for an inadequate response to previous MPH treatment 
was lack of efficacy [LDX 96/127 (75.6 %), ATX 106/135 
(78.5 %)]. The mean optimal dose during the dose-main-
tenance phase (the dose that was dispensed from visit 4) 
was 52.5 mg/day (SD, 16.10) in the LDX group [28/128 
(21.9 %), 36/128 (28.1 %), and 41/128 (32.0 %) patients 
received 30, 50, and 70 mg/day, respectively] and 40.2 mg/
day (20.05) in the ATX group [of patients weighing <70 
kg, 15/134 (11.2 %) and 95/134 (70.9 %) received 0.5 and 
1.2 mg/kg/day, respectively; of patients weighing ≥70 kg, 
2/134 (1.5 %), 1/134 (0.7 %), and 4/134 (3.0 %) patients 
received 40, 80, and 100 mg/day, respectively] [27].
WFIRS‑P scores at baseline
At baseline, mean WFIRS-P total scores and scores in 
each individual domain were similar across both treat-
ment groups (Table 1; Figure S1). Mean WFIRS-P total 
scores were 0.95 (SD 0.474; 95 % CI 0.87, 1.03) in the 
LDX group and 0.91 (SD 0.513; 95 % CI 0.82, 1.00) in 
the ATX group (Table 1). Baseline data were not tested sta-
tistically for equivalence between treatment groups, but, in 
all domains and in total score, the mean score in the LDX 
group lay within the 95 % CI of the mean in the ATX group 
and vice versa (Figure S1).
In both groups, the highest mean scores (indicating the 
greatest degree of impairment) were seen in the Family 
domain [LDX 1.18 (SD 0.733), ATX 1.11 (0.817)] and the 
Learning and School domain [LDX 1.20 (SD 0.657), ATX 
1.19 (0.671)] (Table 1).
Difference between LDX and ATX groups in change 
in WFIRS‑P scores from baseline to endpoint
Compared with ATX treatment, LDX treatment was asso-
ciated with numerically greater LS mean decreases from 
baseline to endpoint in WFIRS-P total score and scores in 
all domains except Life Skills. These differences between 
the LDX and ATX groups were statistically significant for 
total score [p = 0.046; effect size 0.27 (LDX vs ATX)] and 
the domains of Learning and School [p = 0.002; effect 
size 0.43 (LDX vs ATX)] and Social Activities [p = 0.014; 
effect size 0.34 (LDX vs ATX)] (Fig. 1).
Change in WFIRS‑P scores from baseline to week 9 
and endpoint within treatment group
Mean WFIRS-P total and domain scores at week 9 and 
endpoint are shown in Table 1. Both treatments were asso-
ciated with statistically significant reductions from baseline 
(indicating improvement) in LS mean WFIRS-P total score 
at week 9 [LDX −0.37 (95 % CI −0.44, −0.30), ATX 
−0.30 (− 0.36, −0.23); both p < 0.001] and at endpoint 
[LDX −0.35 (95 % CI −0.42, −0.29), ATX −0.27 (− 0.33, 
−0.200); both p < 0.001] (Fig. 2). Reductions from base-
line in LS mean scores in all WFIRS-P domains were also 
significant at week 9 and endpoint in both treatment groups 
Table 1  WFIRS-P total and domain scores at baseline, week 9, and endpoint, mean (SD)
Data are presented as mean (standard deviation). Higher scores indicate greater impairment. Baseline and week 9 scores are based on observed 
values. Endpoint was defined as the last on-treatment, post-baseline visit with a valid assessment. Numbers of observations (n) were in the 
ranges indicated, depending on domain. These data were not analysed statistically
ATX atomoxetine, LDX lisdexamfetamine dimesylate, n number of observations, WFIRS-P Weiss Functional Impairment Rating Scale-Parent 
Report
Baseline Week 9 Endpoint
LDX 
(124 ≤ n ≤ 127)
ATX 
(128 ≤ n ≤ 135)
LDX (92 ≤ n ≤ 95) ATX (93 ≤ n ≤ 97) LDX 
(102 ≤ n ≤ 107)
ATX 
(110 ≤ n ≤ 114)
Family 1.18 (0.733) 1.11 (0.817) 0.66 (0.562) 0.75 (0.635) 0.71 (0.607) 0.80 (0.684)
Learning and school 1.20 (0.657) 1.19 (0.671) 0.54 (0.444) 0.69 (0.551) 0.56 (0.450) 0.72 (0.553)
Life skills 1.07 (0.496) 1.02 (0.571) 0.70 (0.447) 0.66 (0.450) 0.73 (0.472) 0.69 (0.483)
Child’s self-concept 0.83 (0.807) 0.72 (0.830) 0.41 (0.545) 0.39 (0.520) 0.45 (0.583) 0.44 (0.652)
Social activities 0.82 (0.663) 0.83 (0.702) 0.43 (0.427) 0.61 (0.530) 0.46 (0.468) 0.61 (0.544)
Risky activities 0.44 (0.434) 0.39 (0.376) 0.22 (0.228) 0.26 (0.257) 0.23 (0.244) 0.27 (0.260)
Total 0.95 (0.474) 0.91 (0.513) 0.51 (0.308) 0.59 (0.401) 0.54 (0.333) 0.62 (0.412)
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(p < 0.001; Fig. 2). The greatest reductions were seen in 
the Learning and School domain at week 9 [LDX −0.63 
(95 % CI −0.73, −0.54), ATX −0.47 (− 0.57, −0.38)] and 
at endpoint [LDX −0.62 (95 % CI −0.71, −0.52), ATX 
−0.43 (− 0.52, −0.34)].
In both the LDX and ATX treatment groups, the reduc-
tions from baseline to endpoint in LS mean WFIRS-P total 
score were greater than one-half the SD at baseline in the 
Full Analysis Set (0.247; Table S1). Within each individual 
domain, the reductions in LS mean score were greater than 
one-half the SD of the domain score at baseline (Table S1) 
in the domains of Family, Learning and School, and Life 
Skills in the LDX group and in the domains of Learning 
and School and Life Skills in the ATX group.
Discussion
In this 9-week study, both LDX and ATX were associated 
with improvements in WFIRS-P total score and in scores 
across all six WFIRS-P domains in children and adoles-
cents with ADHD who had experienced a clinically inad-
equate response to MPH therapy. The difference in these 
improvements between the LDX and ATX groups was sta-
tistically significant in favour of LDX for WFIRS-P total 
score and the Learning and School and the Social Activities 
domains, with effect sizes (LDX versus ATX) of 0.27, 0.43, 
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adjusted for multiple comparisons. *p < 0.05 and **p < 0.01 LDX 
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and 0.34, respectively. These effect sizes are modest com-
pared with the large effect size (0.924) of LDX versus pla-
cebo for improvement in WFIRS-P total score in a 7-week, 
randomized, double-blind, placebo-controlled study [5]. In 
the present head-to-head study, however, effect sizes are of 
LDX versus the active comparator, ATX, rather than versus 
placebo. Within each treatment group, the changes from 
baseline in WFIRS-P total score and some domain scores 
were greater than one-half SD for the population at base-
line, suggesting that the observed improvements were clini-
cally meaningful. However, the clinical relevance of the 
differences between active treatments in improvements in 
WFIRS-P scores remains to be established.
Depending on their age, patients with ADHD are more 
likely than their peers to underperform at school, to be 
unemployed or on a low income, to have accidents, to be 
arrested, to smoke or abuse substances, to become pregnant 
as teenagers, to contract sexually transmitted diseases, or 
to be divorced [1, 23]. Indeed, functional impairment is a 
diagnostic criterion for ADHD [2, 3, 43], and its impact on 
patients’ lives is commonly a major motivation for seeking 
treatment [37]. Therefore, effective treatments for ADHD 
should both improve symptoms and reduce the functional 
impairments that are associated with the disorder.
Relative to generic measures of function, disease-spe-
cific measures such as the WFIRS-P are believed to maxi-
mize sensitivity by focusing on particular areas of concern 
for patients with a given disorder and, as a result, may be 
especially useful for identifying and measuring treatment 
effects [21]. The sensitivity of the WFIRS-P to treatment-
induced changes in functioning has been demonstrated 
in a limited number of published clinical trials [5, 32, 36, 
39]; however, population-based normative data are not yet 
available [29]. Nevertheless, several unpublished industry-
sponsored, government-funded or academically led inter-
ventional studies registered at clinicaltrials.gov specify the 
WFIRS-P as a secondary outcome measure, indicating its 
increasing acceptance as a measure of functional impair-
ment outcomes in patients with ADHD [9–19].
Mean WFIRS-P total scores at baseline in the present 
study [LDX 0.95 (SD 0.474), ATX 0.91 (0.513)] were 
similar to those reported in two other published large-
scale trials. In a European, 7-week, double-blind, rand-
omized, placebo- and active-controlled study of LDX in 
336 children and adolescents with ADHD, mean WFIRS-
P total scores at baseline were in the range 1.01–1.10 (SD 
0.437–0.456) across the three treatment groups [5]. In an 
international, 12-month, open-label, randomized study 
of ATX compared with ‘other standard therapy’ in 398 
children and adolescents with ADHD, mean WFIRS-P 
scores at baseline were 1.02 (SD 0.475) and 0.96 (0.453) 
in the treatment groups, respectively [32]. All these base-
line values exceed the optimal cut-off score (0.65) for 
differentiating children with and without ADHD, accord-
ing to receiver operating characteristic curve analysis of 
a multicentre observational study [5, 29]. Furthermore, 
in all three studies, the highest mean WFIRS-P scores 
at baseline were observed in the Family domain and 
the Learning and School domain (also referred to as the 
Home domain and School domain [32]), indicating that 
profound impairments in these areas of day-to-day func-
tioning are a consistent finding in clinical studies of chil-
dren and adolescents with ADHD.
Despite differences in study design and patient inclu-
sion/exclusion criteria, the levels of improvement in 
WFIRS-P total and domain scores in the LDX group 
of the present 9-week head-to-head study were simi-
lar to those observed in the previous 7-week placebo-
controlled study of LDX [5]. In both studies, the larg-
est improvements from baseline in the LDX group were 
observed in the Learning and School domain, followed 
by the Family domain, and the smallest improvements 
were seen in the Life Skills and the Risky Activities 
domains. In the placebo-controlled study, the improve-
ments from baseline were statistically significantly 
superior to placebo for WFIRS-P total score and the 
domains of Learning and School, Family, Social Activi-
ties, and Risky Activities. Some patients from the Euro-
pean placebo-controlled study, together with additional 
US patients, took part in a follow-up study of the long-
term maintenance of efficacy of LDX [24], which also 
included the WFIRS-P as a secondary efficacy measure. 
In the open-label period of at least 26-week LDX treat-
ment, WFIRS-P scores improved in all domains and 
in total [4]. In the subsequent 6-week, double-blind, 
placebo-controlled, randomized-withdrawal period, 
WFIRS-P scores deteriorated in the placebo group in 
all domains and in total, and the difference between the 
LDX and placebo groups was statistically significant for 
WFIRS-P total score and the domains of Family, Learn-
ing and School, and Risky Activities [4].
In the present study, the largest changes from baseline 
in the ATX group were observed in the Family domain and 
the Learning and School domain, as was also the case in the 
LDX group. These domains also saw the largest changes 
from baseline in both treatment arms of the 12-month 
open-label study comparing ATX with ‘other standard 
therapy’ (mainly MPH) [32] and in the osmotic-release oral 
system MPH (OROS-MPH) reference arm of the 7-week 
European, placebo-controlled study of LDX [5]. This ref-
erence arm was included to validate the study design and 
contextualize the results; statistical comparisons of OROS-
MPH versus LDX were not pre-specified [22].
Taken together, the available data therefore suggest that 
the Learning and School and the Family domains of the 
WFIRS-P are most responsive to therapy, as well as most 
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affected at baseline. This does not necessarily mean, how-
ever, that the effects of different classes of ADHD medication 
on different domains of functional impairment are equiva-
lent. For example, in the present study, LDX was statistically 
significantly superior to ATX in total score and in the Social 
Activities and the Learning and School domains, but not 
in other domains. Also, in the 7-week, European, placebo-
controlled study of LDX, the effect sizes for WFIRS-P total 
score of LDX versus placebo and of the OROS-MPH refer-
ence treatment versus placebo were both large (0.924 and 
0.772, respectively), but the placebo-adjusted effects of the 
two medications were not identical across the six WFIRS-P 
domains [5] (no post hoc statistical analysis comparing LDX 
versus OROS-MPH has been published for these outcomes, 
in contrast to the primary efficacy outcome [38]). The poten-
tial implications of these findings and the present results for 
individualized patient management remain to be established.
Although the present study did not investigate the time 
course of changes in WFIRS-P scores, evidence from pre-
vious studies suggests that the rate of response to treatment 
may differ across WFIRS-P domains. First, within both the 
LDX arm and OROS-MPH reference arm of the European, 
placebo-controlled study of LDX, some domains did not 
show improvement from baseline until week 7, whereas 
improvement from baseline in others was evident at week 4 
[5]. Secondly, most, but not all, of the improvement from 
baseline in WFIRS-P scores in the open-label period of 
the subsequent randomized-withdrawal study occurred 
before week 8 [4]. Thirdly, in the long-term, open-label 
comparison of ATX with ‘other standard therapy’, the 
only statistically significant difference in WFIRS-P scores 
between groups was in favour of ‘other standard therapy’ 
in the Learning and School domain at 6 months (p < 0.05); 
this difference was not evident after 12 months of treat-
ment [32]. These observations suggest that some domains 
of functional impairment may be more likely than other 
aspects of ADHD to respond to pharmacotherapy over a 
longer treatment period than was used in the present study.
The associations between ADHD symptoms, functional 
impairments, and health-related quality of life (HRQoL) 
have yet to be fully understood. HRQoL instruments measure 
a patient’s (or a parent’s) subjective perception of the impact 
of health status on their (or their child’s) physical, psycho-
logical, and social well-being [26]. Studies investigating the 
correlations between ADHD symptom severity ratings and 
HRQoL scores have revealed statistically significant, but 
only moderately strong, correlations between the two meas-
ures (r = 0.2–0.6), supporting the view that symptoms and 
HRQoL represent related but distinct constructs [26]. There 
are, however, few data available to establish the interactions 
between functional impairment and either ADHD symp-
toms or HRQoL. Analyses have indicated a statistically sig-
nificant, but imperfect, correlation between functioning and 
HRQoL, suggesting that these too are related but distinct 
constructs [20]. This is consistent with the observation in 
the present study that the effect sizes of LDX versus ATX 
for WFIRS-P scores (total score 0.27, Learning and School 
0.43, Social Activities 0.34, all p < 0.05) were smaller than 
for the previously reported ADHD-RS-IV symptomatologi-
cal outcome measure (0.56; p < 0.001) [27]. Effect sizes for 
LDX and OROS-MPH versus placebo were also larger for 
ADHD-RS-IV total score than for WFIRS-P scores in the 
previous 7-week, European, placebo-controlled study [5, 
22]. Further studies and analyses are required to increase 
the understanding of the interrelationships between ADHD 
symptoms, functional impairment, and HRQoL.
The safety outcomes of the present study have been pub-
lished previously and were consistent with those of earlier 
clinical trials [27]. In summary, treatment-emergent adverse 
events were reported by similar proportions of patients in 
each treatment group (LDX 71.9 %, ATX 70.9 %). [27] 
Weight loss was larger in the LDX group than in the ATX 
group, and the proportion of patients who met the outlier 
criterion for high pulse rate (≥100 beats per minute) was 
higher in the ATX group than in the LDX group [27]. With 
these exceptions, the changes in mean vital signs and elec-
trocardiogram parameters, the proportions of patients meet-
ing other outlier criteria, and the frequency of potentially 
clinically important vital sign observations were all similar 
for LDX and ATX treatment [27].
Strengths of the present study include the sample 
size, the head-to-head, randomized, double-blind, dose-
optimized design, and the geographically diverse patient 
population. Patients were required to have experienced 
an inadequate response to MPH therapy, making the pre-
sent findings particularly relevant in European countries in 
which LDX is approved for the treatment of children and 
adolescents when response to previous MPH treatment is 
considered clinically inadequate by the supervising special-
ist. Although the definition of inadequate response to MPH 
therapy was broad, lack of efficacy was the most common 
reason given for an inadequate response.
An important limitation of the study is the relatively 
short duration of treatment, which precludes evaluation of 
the long-term effects of treatment on functional impair-
ment. The observation that it may take 12 or more weeks 
for ATX to reach its maximum effect on ADHD symptoms 
[42] suggests the possibility that the 9-week duration of the 
study may have led to an underestimation of the efficacy of 
ATX. Improvements in functioning may occur over a longer 
treatment period than relief of symptoms, potentially also 
leading to underestimation of the effects of treatment on 
functional impairment as a secondary outcome in the pre-
sent study. Furthermore, although the dose-titration sched-
ules of both treatments followed current guidelines, twice-
daily ATX and/or higher doses of ATX may have been more 
148 Eur Child Adolesc Psychiatry (2016) 25:141–149
1 3
effective than the once-daily dosing required in the present 
study [35]. Finally, the possibility cannot be excluded that 
patients’ experience of MPH treatment before enrolment 
may have led to preconceptions regarding the ADHD medi-
cations under investigation (perhaps relating to their onset 
or duration of efficacy or tolerability), which might have 
influenced functional outcomes in this double-blind study.
In conclusion, this study has shown that both LDX and 
ATX treatment can improve functioning, as measured by 
the WFIRS-P, in children and adolescents with ADHD who 
have experienced a clinically inadequate response to MPH 
(as judged by investigators). Improvements overall and in 
certain domains were statistically significantly greater in 
magnitude with LDX treatment than with ATX treatment, 
within the time frame of the study. These findings may aid 
clinicians when developing treatment plans to address the 
functional impairments associated with ADHD.
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